References
- Safdar A. Strategies to enhance immune function in hematopoietic transplantation recipients who have fungal infections. Bone marrow Transplant 2006; 38: 327–337
- Herbrecht R, Denning D W, Patterson T F, Bennett J E, Greene R E, Oestmann J W, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408–415
- Trifilio S, Pennick G, Pi J, et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007; 109: 1532–1535
- Trifilio S M, Bennett C L, Yarnold P R, et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007; 39: 425–429
- Raad I I, Hachem R Y, Herbrecht R, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006; 42: 1398–1403
- Ezzet F, Wexler D, Courtney R, Krishna G, Lim J, Laughlin M. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet 2005; 44: 211–220
- Safdar A, Rodriguez G H, Lichtiger B, et al. Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions. Cancer 2006; 106: 2664–2671
- Heyn K, Tredup A, Salvenmoser S, Muller F M. Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani. Antimicrob Agents Chemother 2005; 49: 5157–5159
- Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2004; 57: 218–222
- Courtney R, Sansone A, Calzetta A, Marinho M, Laughlin M. The effect of a nutritional supplement (Boost Plus) on the oral bioavailability of posaconazole [abstract]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September, 14 – 172003, Abstract M-1604
- Ullmann A J, Cornely O A, Bruchardt A, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrobial Agents Chemother 2006; 50: 658–666
- Walsh T, Patterson T, Langston A, et al. Posaconazole for treatment of invasive aspergillosis in patients who are refractory to or intolerant of conventional therapy: an externally controlled blinded trial. Clin Infect Dis 2007; 44: 2–12
- Noxafil. Schering Corporation, Kenilworth, NJ September, 2006
- Arkan S, Lozano-Chiu M, Paetznick V, Rex J H. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrobial Agents Chemother 2002; 46: 245–247
- Gil-Lamaignene C, Simitsopoulou M, Roilides E, Maloukou A, Winn R M, Walsh T J. Interferon-gamma and granulocyte-macrophge colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes. J Infect Dis 2005; 191: 1180–1187
- Roilides E, Holmes A, Blake C, Venzon D, Pizzo P A, Walsh T J. Antifungal activity of elutriated human monocytes against Aspergillus fumigatus haphae: enhancement by granulocyte-macrophage colony-stimulating factor and interferon-gamma. J Infect Dis 1994; 170: 894–899